Isturisa denied due to quantity / dose limits by Cigna?

Cigna's specific coverage criteria for isturisa are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Isturisa Due to Quantity Limits

A quantity-limit denial means Cigna's benefit plan restricts the amount of Isturisa (osilodrostat) that can be dispensed within a given time period — typically a monthly supply ceiling — and the prescription as written exceeded that limit. For Cushing's disease, the appropriate dosing regimen is individualized by the treating endocrinologist based on the patient's hormonal response and tolerability, and the standard quantity limit may not accommodate the medically necessary amount for every patient.

Quantity-limit exceptions are routinely available and routinely granted when the prescriber documents the clinical rationale for the prescribed quantity. This denial is very commonly resolved at the internal appeal stage.

## Federal Appeal Framework

• ACA §2719 / ERISA §503: You have the right to a full internal appeal of a quantity-limit denial, including the right to receive the specific criteria Cigna applied and to have a physician reviewer involved in the determination.
• External review: If the internal appeal is denied, you may escalate to an IRO. You generally have approximately four months from the denial date to request external review — confirm the exact deadline from your denial letter.
• Expedited option: If your medical condition makes the standard quantity insufficient in a way that creates urgent clinical risk, request expedited review.

## Concrete Appeal Process and Timeline

1. File a written quantity-limit exception request with Cigna, supported by the prescriber's documentation of the clinical rationale for the prescribed quantity. 2. If the exception is denied, file a formal internal appeal within Cigna's stated deadline (typically 180 days from the denial). 3. Cigna must respond to a prospective internal appeal within 30 days or a retrospective appeal within 60 days. 4. If denied internally, escalate to IRO external review before the four-month window closes.

## Documentation to Gather

• Diagnosis confirmation: Endocrinology records confirming active Cushing's disease and the biochemical basis for current treatment.
• Dosing rationale per the chart: Office notes documenting why the prescribed quantity is medically necessary — specifically, the clinical factors (hormonal response, titration process, tolerability) that the endocrinologist used to arrive at the prescribed amount. The FDA-approved prescribing information for Isturisa describes the authorized dose range and titration approach; the prescriber should document how the patient's clinical course aligns with that approved range.
• Clinical severity: Documentation of disease activity and the consequences of receiving less than the prescribed amount.
• Prescriber medical-necessity letter: A letter from the treating endocrinologist that explains the individualized clinical rationale for the quantity prescribed, references the FDA-approved dosing range in the prescribing label, and states why the plan's standard quantity limit is insufficient for this patient's care.

## Criteria-Mapping Structure

Obtain Cigna's quantity-limit policy for Isturisa and the criteria for a quantity-limit exception. Map your evidence to each criterion:

| Exception Criterion | Patient-Specific Evidence | |---|---| | Prescribed quantity falls within FDA-approved dosing range | [Reference to FDA label dosing section; prescriber confirmation] | | Clinical factors requiring quantity above plan default | [Chart notes documenting titration, hormonal response, tolerability] | | Exceeding standard limit is medically necessary | [Prescriber letter with chart-based rationale] |

Attach all referenced records. For quantity-limit appeals, the most effective evidence is a clear, chart-supported explanation from the endocrinologist — ideally tied directly to the dosing guidance in the FDA prescribing label — of why the prescribed amount is appropriate for this individual patient.